Unum Therapeutics (NASDAQ:UMRX) posted its quarterly earnings results on Monday. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.05, Bloomberg Earnings reports. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.10 million.
NASDAQ:UMRX opened at $1.91 on Wednesday. The firm’s fifty day moving average price is $2.24. Unum Therapeutics has a 52 week low of $1.50 and a 52 week high of $16.72. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.11. The company has a market cap of $55.12 million, a price-to-earnings ratio of -1.37 and a beta of 1.38.
Large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Unum Therapeutics by 281.5% in the 4th quarter. BlackRock Inc. now owns 1,530,419 shares of the company’s stock worth $6,733,000 after purchasing an additional 1,129,262 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in Unum Therapeutics by 7.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock worth $242,000 after purchasing an additional 3,846 shares in the last quarter. Deutsche Bank AG raised its holdings in Unum Therapeutics by 72.4% in the 4th quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock worth $279,000 after purchasing an additional 26,742 shares in the last quarter. Rhumbline Advisers bought a new position in Unum Therapeutics in the 1st quarter worth $85,000. Finally, Northern Trust Corp raised its holdings in Unum Therapeutics by 312.6% in the 4th quarter. Northern Trust Corp now owns 178,640 shares of the company’s stock worth $786,000 after purchasing an additional 135,345 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
See Also: Market Capitalization
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.